News
The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.
April serves as Testicular Cancer Awareness Month, which is the most common type of cancer in men aged between 15 and 44 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback